Lifecore Biomedical (NASDAQ:LFCR) Price Target Raised to $9.00 at Stephens

Lifecore Biomedical (NASDAQ:LFCR) had its target price hoisted by Stephens from $8.00 to $9.00 in a research note released on Friday, Marketbeat reports. The brokerage currently has an equal weight rating on the stock.

Separately, Barrington Research reduced their target price on Lifecore Biomedical from $11.00 to $10.00 and set an outperform rating for the company in a report on Friday.

Lifecore Biomedical Price Performance

Shares of LFCR opened at $7.87 on Friday. The company has a current ratio of 2.35, a quick ratio of 1.05 and a debt-to-equity ratio of 3.36. The stock’s 50 day moving average is $9.64 and its two-hundred day moving average is $6.93. Lifecore Biomedical has a twelve month low of $1.52 and a twelve month high of $11.45. The firm has a market capitalization of $238.63 million, a PE ratio of -2.31 and a beta of 1.09.

Lifecore Biomedical (NASDAQ:LFCR) last posted its quarterly earnings results on Thursday, June 1st. The company reported ($0.22) earnings per share for the quarter. Lifecore Biomedical had a negative net margin of 64.29% and a negative return on equity of 35.52%. The business had revenue of $27.60 million during the quarter. During the same quarter in the previous year, the business posted ($0.08) EPS. Research analysts anticipate that Lifecore Biomedical will post -0.96 earnings per share for the current year.

Institutional Investors Weigh In On Lifecore Biomedical

A number of hedge funds and other institutional investors have recently modified their holdings of LFCR. Tower Research Capital LLC TRC acquired a new stake in shares of Lifecore Biomedical in the 2nd quarter worth approximately $60,000. Barclays PLC purchased a new stake in Lifecore Biomedical during the second quarter worth $87,000. Charles Schwab Investment Management Inc. purchased a new position in shares of Lifecore Biomedical in the second quarter valued at $101,000. Mirabella Financial Services LLP purchased a new position in shares of Lifecore Biomedical in the second quarter valued at $149,000. Finally, Gabelli Funds LLC acquired a new position in shares of Lifecore Biomedical during the 2nd quarter worth $161,000. 75.85% of the stock is currently owned by institutional investors and hedge funds.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.